Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2008 1
2009 3
2010 7
2011 9
2012 4
2013 5
2014 4
2015 9
2016 10
2017 5
2018 9
2019 7
2020 9
2021 14
2022 9
2023 13
2024 11
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jan;271(1):141-176. doi: 10.1007/s00415-023-11910-z. Epub 2023 Sep 7. J Neurol. 2024. PMID: 37676297 Free PMC article. Review.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: pul r. Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15. Autoimmun Rev. 2023. PMID: 36924922 Free article. Review.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Könnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, Kümpfel T, Berger R, Röther J, Häußler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, Hümmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100. doi: 10.1212/NXI.0000000000001100. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34785575 Free PMC article.
Gute Ernährung reduziert MS-Symptome.
Pul R, Kleinschnitz C. Pul R, et al. MMW Fortschr Med. 2018 Oct;160(18):42. doi: 10.1007/s15006-018-1026-7. MMW Fortschr Med. 2018. PMID: 30350066 Review. German. No abstract available.
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Möllenhoff K, Pfeuffer S. Meuth SG, et al. Among authors: pul r. Ann Neurol. 2025 Mar;97(3):583-595. doi: 10.1002/ana.27143. Epub 2024 Nov 25. Ann Neurol. 2025. PMID: 39582359 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, Revie L, Giglhuber K, Häußler V, Karenfort M, Hellwig K, Paul F, Bellmann-Strobl J, Otto C, Ruprecht K, Ziemssen T, Emmer A, Rothhammer V, Nickel FT, Angstwurm K, Linker R, Laurent SA, Warnke C, Jarius S, Korporal-Kuhnke M, Wildemann B, Wolff S, Seipelt M, Yalachkov Y, Retzlaff N, Zettl UK, Rommer PS, Kowarik MC, Wickel J, Geis C, Hümmert MW, Trebst C, Senel M, Gold R, Klotz L, Kleinschnitz C, Meuth SG, Aktas O, Berthele A, Ayzenberg I; German Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Among authors: pul r. Neurology. 2024 Nov 12;103(9):e209888. doi: 10.1212/WNL.0000000000209888. Epub 2024 Oct 1. Neurology. 2024. PMID: 39353149 Free PMC article.
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.
Häußler V, Trebst C, Engels D, Pellkofer H, Havla J, Duchow A, Schindler P, Schwake C, Pakeerathan T, Fischer K, Ringelstein M, Lindenblatt G, Hümmert MW, Tkachenko D, Bütow F, Giglhuber K, Flaskamp M, Schiffmann I, Korporal-Kuhnke M, Jarius S, Dawin E, Revie L, Senel M, Herfurth M, Walter A, Pompsch M, Kleiter I, Angstwurm K, Kaste M, Grothe M, Wickel J, Rommer PS, Sieb JP, Krämer M, Then Bergh F, Tumani H, Klotz L, Wildemann B, Aktas O, Ayzenberg I, Bellmann-Strobl J, Paul F, Kümpfel T, Friede T, Berthele A, Stellmann JP; Neuromyelitis optica study group (NEMOS). Häußler V, et al. J Neurol Neurosurg Psychiatry. 2025 May 14;96(6):582-592. doi: 10.1136/jnnp-2024-334764. J Neurol Neurosurg Psychiatry. 2025. PMID: 39730197 Free PMC article.
128 results